Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,034
datasets available to search
ShareScore release 0.9.0
Dataset results
1,034 results for “Cirrhosis”
TCIA/TGCA-LIHC portal venous phase CT-scans for cirrhosis classification
<p>These are the scans provided by The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) data collection, published by The Cancer Imaging Archive <a href="https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=6885436">here</a> and used in our <a href="https://arxiv.org/abs/2307.04617">MICCAI 2023 paper</a>. You can find the GitHub of the paper <a href="https://arxiv.org/abs/2307.04617">here</a>.</p> <p>All the data are submitted to <a href="https://wiki.cancerimagingarchive.net/display/Public/Data+Usage+Policies+and+Restrictions">TCIA data usage policy</a> and must be strictly respected by future users.</p> <p>The selected scans are in portal venous phase, which is the phase that is clinically used to identify cirrhosis. In this list, you will find all the patients available in the TCGA-LIHC database, regardless of the availability of the annotations or the duplicated patients at different dates. In the dataframe provided in the Git repo, you will find the dataframe with one scan per patient (only at the first date), and with the Ishak score for each patient provided in the TCIA/TGCA database, which are the exact ones that we used in the paper. The names of the scans in the dataframe match exactly the ones below, to ease reproducibility. </p> <p>The scans are already pre-processed and are the exact ones that we use in evaluation phase in the published paper.</p>
Raw Data for the article: Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant Enterobacterales in Decompensated Cirrhosis
<p><strong>Background: </strong>Spontaneous bacterial peritonitis (SBP) is a severe and often fatal infection in patients with decompensated cirrhosis and ascites. The only cure for SBP is antibiotic therapy, but the emerging problem of bacterial resistance requires novel therapeutic strategies. Human amniotic mesenchymal stromal cells (hA-MSCs) possess immunomodulatory and anti-inflammatory properties that can be harnessed as a therapy in such a context.</p> <p><strong>Methods: </strong>An in vitro applications of hA-MSCs in ascitic fluid (AF) of cirrhotic patients, subsequently infected with carbapenem-resistant Enterobacterales, was performed. We evaluated the effects of hA-MSCs on bacterial load, innate immunity factors, and macrophage phenotypic expression.</p> <p><strong>Results: </strong>hA-MSCs added to AF significantly reduce the proliferation of both bacterial strains at 24 h and diversely affect M1 and M2 polarization, C3a complement protein, and ficolin 3 concentrations during the course of infection, in a bacterial strain-dependent fashion.</p> <p><strong>Conclusion: </strong>This study shows the potential usefulness of hA-MSC in treating ascites infected with carbapenem-resistant bacteria and lays the foundation to further investigate antibacterial and anti-inflammatory roles of hA-MSC in in vivo models.</p>
Raw Data for the article: Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model
<p><strong>Background and aims: </strong>Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) improves survival in patients with cirrhosis with refractory ascites and portal hypertensive bleeding. However, the indication for TIPS in older adult patients (greater than or equal to 70 years) is debated, and a specific prediction model developed in this particular setting is lacking. The aim of this study was to develop and validate a multivariable model for an accurate prediction of mortality in older adults.</p> <p><strong>Approach and results: </strong>We prospectively enrolled 411 consecutive patients observed at four referral centers with de novo TIPS implantation for refractory ascites or secondary prophylaxis of variceal bleeding (derivation cohort) and an external cohort of 415 patients with similar indications for TIPS (validation cohort). Older adult patients in the two cohorts were 99 and 76, respectively. A cause-specific Cox competing risks model was used to predict liver-related mortality, with orthotopic liver transplant and death for extrahepatic causes as competing events. Age, alcoholic etiology, creatinine levels, and international normalized ratio in the overall cohort, and creatinine and sodium levels in older adults were independent risk factors for liver-related death by multivariable analysis.</p> <p><strong>Conclusions: </strong>After TIPS implantation, mortality is increased by aging, but TIPS placement should not be precluded in patients older than 70 years. In older adults, creatinine and sodium levels are useful predictors for decision making. Further efforts to update the prediction model with larger sample size are warranted.</p>
DECISION Masterclass 2022 - Overview of the effects of LMWH in cirrhosis (Agustín Albillos Martínez)
<p>https://decision-for-liver.eu/</p> <p>The objective of the DECISION project is to enhance the understanding of the pathophysiology of decompensation of #cirrhosis leading to acute-on-chronic liver failure (#ACLF) or death. This consortium will take advantage of already existing large and clinically well-characterized cohorts to ultimately develop prognostic and response tests and combinatorial therapies tailored to the needs of individual patients to decrease the risk of short-term death. In this masterclass, DECISION consortium member Prof. Dr. Agustín Albillos Martínez (Department Head Gastroenterology and Hepatology at "Ramón y Cajal" Hospital & Professor of Medicine at the University of Alcalá), provided an overview of the effects of low molecular weight #heparin (#LMWH) in #cirrhosis. In his lecture, he gave a brief refresher on the mode of action of anti-coagulants, followed by the pathophysiological basis for the long-term use of #anticoagulation in cirrhosis as well as the experience with anticoagulants in the clinic. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847949. This video reflects only the presenter's view and the European Commission is not responsible for any use that may be made of the information it contains.</p> <p>Video recording: Dr. Ameli Schwalber</p> <p>Video production: Tassilo Steinmann & Dr. Nina Donner</p> <p>Video subtitles: Nicolas Lupke & Tamara Breitinger</p> <p>https://concentris.de © 2023 DECISION</p>
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
ClinicalTrials.gov study NCT00550862. IPD Sharing: Not stated. Countries: 8. Publications: 1.
An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
ClinicalTrials.gov study NCT01640964. IPD Sharing: Not stated. Countries: 1. Publications: 1.
FMT in Cirrhosis and Hepatic Encephalopathy
ClinicalTrials.gov study NCT03796598. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
ClinicalTrials.gov study NCT02673489. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Probiotics for Liver Cirrhosis With Portal Hypertension
ClinicalTrials.gov study NCT01598064. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
ClinicalTrials.gov study NCT02609048. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
ClinicalTrials.gov study NCT02960204. IPD Sharing: NO. Countries: 3. Publications: 1.
Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design
ClinicalTrials.gov study NCT06977685. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
ClinicalTrials.gov study NCT02639338. IPD Sharing: YES. Countries: 8. Publications: 1.
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
ClinicalTrials.gov study NCT02994056. IPD Sharing: YES. Countries: 2. Publications: 0.
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (
ClinicalTrials.gov study NCT03449446. IPD Sharing: NO. Countries: 6. Publications: 1.
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
ClinicalTrials.gov study NCT01672879. IPD Sharing: Not stated. Countries: 8. Publications: 3.
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
ClinicalTrials.gov study NCT02201901. IPD Sharing: YES. Countries: 2. Publications: 3.
Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial
ClinicalTrials.gov study NCT04448028. IPD Sharing: YES. Countries: 1. Publications: 1.
Use of Fenofibrate for Primary Biliary Cirrhosis
ClinicalTrials.gov study NCT00575042. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
ClinicalTrials.gov study NCT02996682. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.